CCR5 antagonist maraviroc alleviates doxorubicin-induced neuroinflammation and neurobehavioral deficiency by regulating NF-κB/NLRP3 signaling in a breast cancer mouse model
Authors:
- 3 May 2024
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 254, 109981
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
This publication has 56 references indexed in Scilit:
- In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedinBiomedicine & Pharmacotherapy, 2024
- Wnt3a/GSK3β/β-catenin Signalling Modulates Doxorubicin-associated Memory Deficits in Breast CancerMolecular Neurobiology, 2024
- Neuroimmune reactivity marker expression in rodent models of chemotherapy-induced cognitive impairment: A systematic scoping reviewBrain, Behavior, and Immunity, 2021
- Insight into the roles of CCR5 in learning and memory in normal and disordered statesBrain, Behavior, and Immunity, 2021
- CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancerCellular Oncology, 2018
- Dysregulation in myelination mediated by persistent neuroinflammation: Possible mechanisms in chemotherapy-related cognitive impairmentBrain, Behavior, and Immunity, 2014
- Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment researchSupportive Care in Cancer, 2011
- Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancerCancer, 2010
- Cognitive impairments associated with breast cancer treatments: results from a longitudinal studyBreast Cancer Research and Treatment, 2008
- Biology of CCR5 and Its Role in HIV Infection and TreatmentJAMA, 2006